AU Patent
AU2010326798A1 — Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Assigned to Glaxo Group Ltd · Expires 2012-06-21 · 14y expired
What this patent protects
Novel combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
USPTO Abstract
Novel combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
Drugs covered by this patent
- Arnuity Ellipta (FLUTICASONE FUROATE) · Haleon Us Holdings
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.